Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Licensing revenue	$ 220,233		$ 220,233
Operating expenses:
Research and development	559,177	677,151	1,514,257	1,767,942
Clinical and regulatory	1,133,956	3,718,902	5,613,209	9,261,529
General and administrative	820,574	947,392	2,935,030	3,150,394
Total operating expenses	2,513,707	5,343,445	10,062,496	14,179,865
Loss from operations	(2,293,474)	(5,343,445)	(9,842,263)	(14,179,865)
Interest income	5,445	20,121	24,400	49,970
Other income, net	734,509	4,449	757,044	29,909
Interest expense	(110,468)	(108,834)	(370,422)	(257,339)
Total non-operating income (expenses), net	629,486	(84,264)	411,022	(177,460)
Net loss	(1,663,988)	(5,427,709)	(9,431,241)	(14,357,325)
Net loss - non-controlling interest	(47,042)	(242,244)	(329,471)	(549,190)
Net loss attributable to Heat Biologics, Inc.	$ (1,616,946)	$ (5,185,465)	$ (9,101,770)	$ (13,808,135)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted	$ (0.08)	$ (0.62)	$ (0.59)	$ (1.75)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted	19,420,026	8,408,376	15,371,267	7,880,637
Other comprehensive loss:
Net loss	$ (1,663,988)	$ (5,427,709)	$ (9,431,241)	$ (14,357,325)
Unrealized loss on foreign currency translation	(36,387)	(27,244)	(62,961)	(64,238)
Total other comprehensive loss	(1,700,375)	(5,454,953)	(9,494,202)	(14,421,563)
Comprehensive loss attributable to non-controlling interest	(47,042)	(242,244)	(329,471)	(549,190)
Comprehensive loss	$ (1,653,333)	$ (5,212,709)	$ (9,164,731)	$ (13,872,373)